Classification of neuroendocrine tumors -- Molecular genetics of Pheochromocytoma and paraganglioma -- Molecular Genetics of MEN1-related Neuroendocrine Tumors -- Molecular genetics of MEN2-related neuroendocrine tumors -- Molecular genetics of Neuroblastoma -- Molecular Genetics of Gastroenteropancreatic Neuroendocrine Tumors -- Current and future radiopharmaceuticals in neuroendocrine tumors imaging -- SPECT/CT, PET/CT and PET/MR: Principles -- Internal dosimetry: Principles and Applications to NET -- Principles and Application of Molecular Imaging for Personalised Medicine and Guiding Interventions in Neuroendocrine Tumors -- Tumor metabolism and metabolomics of pheochromocytomas and paragangliomas -- Radionuclide imaging of pheochromocytoma and paraganglioma in the era of multi-omics -- Radionuclide imaging of Head and neck PGLs -- Radionuclide imaging of Chromaffin cell tumors -- Radionuclide imaging of Gastrointestinal neuroendocrine tumors -- Radionuclide imaging of Pancreatic neuroendocrine tumors -- Radionuclide imaging of Pulmonary, thymic neuroendocrine tumors and other neuroendocrine tumors -- Radionuclide imaging of Medullary thyroid carcinoma -- 131I-MIBG therapy for pheochromocytoma/paraganglioma and neuroblastoma -- Somatostatin receptors-based radionuclide therapy -- Alpha radionuclide therapy: Principles and Applications to NET -- Nanoparticles for Radionuclide Imaging and Therapy: Principles.

Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, and alpha radionuclide therapy, as well as the role of nanoparticles. Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.

Available to subscribing member institutions only. Доступно лише організаціям членам підписки.

Online access from local network of NaUOA.

Online access with authorization at https://link.springer.com/

Онлайн-доступ з локальної мережі НаУОА.

Онлайн доступ з авторизацією на https://link.springer.com/